2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P6441
    KP-6 2102414-23-1 98%
    KP-6, a polypeptide, is a Wnt/β-catenin signal inhibitor. KP-6 inhibits TGF-β and blocks rush fibrosis signal path crucial in vivo. KP-6 suppresses Renal tissues damage and renal fibrosis, and reverse the course of disease of chronic kidney disease (CKD).
    KP-6
  • HY-P6442
    Chemerin15 1020407-90-2
    Chemerin15 is a chemerin peptide that enhances macrophage (MPhi) phagocytosis of microbial particles and apoptotic cells. Chemerin15 inhibits MΦ activation and suppress peritonitis induced by the yeast cell wall component zymosan.
    Chemerin15
  • HY-P9942
    Sulesomab 167747-19-5
    Sulesomab (IMMU-MN3) is a murine monoclonal antibody fragment of the IgG1 class that binds to Normal Cross-Reactive Antigen-90 present on leukocytes. Sulesomab is cleared into infection nonspecifically through increased capillary membrane permeability.
    Sulesomab
  • HY-Z8754
    Tacrolimus 8-epimer 129212-35-7 98%
    Tacrolimus anhydrous 8-epimer (Tacrolimus EP impurity D) is a l-pipecolic acid macrolide lactone, an important immunosuppressive agent that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2.
    Tacrolimus 8-epimer
  • HY-100084
    Methyl-3β-hydroxycholenate 20231-57-6 98%
    Methyl-3β-hydroxycholenate is a ROR gamma modulator extracted from patent US20110263046 A1, in figure 2.
    Methyl-3β-hydroxycholenate
  • HY-100087
    Budesonide impurity C 1040085-99-1 98.58%
    Budesonide impurity C is an impurity of Budesonide. Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist.
    Budesonide impurity C
  • HY-100125
    Timegadine 71079-19-1 98%
    Timegadine, a new antiinflammatory agent, is found to be a potent, competitive inhibitor of cyclo-oxygenase (COX) and lipo-oxygenase, with IC50s ranging from 5 nM (washed rabbit platelets) to 20 μM (rat brain) for COX and 100 μM for lipo-oxygenase both in the cytosol fraction of horse platelet homogenates, and in washed rabbit platelets.
    Timegadine
  • HY-100139
    Diflumidone 22736-85-2 98%
    Diflumidone is a non-steroidal antiinflammatory agent.
    Diflumidone
  • HY-100142
    Clozic 22494-47-9 98%
    Clozic is a potential anti-arthritic agent.
    Clozic
  • HY-100146
    Pirazolac 71002-09-0 98%
    Pirazolac is a non-steroidal anti-inflammatory drug.
    Pirazolac
  • HY-100148
    ICI 211965 129424-08-4 98%
    ICI 211965 (ZM-211965) is a selective and orally potent 5-Lipoxygenase (5-LPO) inhibitor.
    ICI 211965
  • HY-100162
    TOK-8801 105963-46-0 98%
    TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator.
    TOK-8801
  • HY-100173
    DW-1350 491577-61-8 98%
    DW-1350 is a LTB4 receptor antagonist.
    DW-1350
  • HY-10017A
    (R)-SCH 546738 2181148-54-7 99.75%
    (R)-SCH 546738 is the R-isomer of SCH 546738 (HY-10017). SCH 546738 is an orally active and non-competitive antagonist for CXCR3 with Ki of 0.4 nM for human CXCR3 receptor.
    (R)-SCH 546738
  • HY-100191
    BMY-25271 78441-82-4 98%
    BMY-25271 is a histamine H2 receptor antagonist.
    BMY-25271
  • HY-100194
    FKK 78299-79-3 98%
    FKK is an indazole derivative and also a novel bronchodilator.
    FKK
  • HY-10020S
    Varenicline-15N3 hydrochloride 1244134-80-2 98%
    Varenicline-15N3 Hydrochloride (CP 526555-15N3 Hydrochloride) is the 15N labeled isotope of Varenicline hydrochloride (HY-10020). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline-15N3 hydrochloride
  • HY-100210
    FN-439 124168-73-6 98%
    FN-439 is a selective collagenase-1 inhibitor. FN-439 inhibits collagenase-1 with an IC50 value of 1 μM. FN-439 can be used for the research of cancer and inflammation.
    FN-439
  • HY-100241
    Nafocare B1 93135-89-8 98%
    Nafocare B1 is a synthetic immune biological response modifier.
    Nafocare B1
  • HY-100250
    Spirofylline 98204-48-9 98%
    Spirofylline is a bronchodilator that has the potential for asthma and bronchitis and emphysema treatment.
    Spirofylline
Cat. No. Product Name / Synonyms Application Reactivity